InMed's INM-901 Shows Promise in Human Brain Organoid Models for Alzheimer's Disease Treatment
核心洞察
InMed Pharmaceuticals reported positive preclinical data showing INM-901 significantly reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
The compound demonstrated dose-dependent reduction of key pro-inflammatory markers IL-6 and IL-8 (搜索) in both general neuroinflammation and Alzheimer's-specific organoid models.
Results provide supportive evidence for mechanistic translation from animal models to human tissue systems, de-risking the program ahead of planned Phase 1 clinical trials.
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced positive preclinical data demonstrating that its investigational compound INM-901 significantly reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease. The studies, conducted in collaboration with Stem Pharm (搜索), Inc., represent a critical step in translating prior animal model results into human-relevant systems ahead of first-in-human clinical trials.
Breakthrough in Human Brain Organoid Testing
The research utilized advanced in vitro human organoid models that represent some of the closest approximations to human brain tissue currently available. These sophisticated models incorporate neurons, astrocytes, vascular cells, and microglia—the brain's resident immune cells—creating a complex cellular environment relevant to neurodegenerative disease.
INM-901 was evaluated in two distinct human 3D organoid models: a general neuroinflammation model induced with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), and Stem Pharm (搜索)'s proprietary neuroinflammation Alzheimer's disease model featuring specific characteristics observed in Alzheimer's patients.
Significant Anti-Inflammatory Effects
The compound demonstrated significant reduction in neuroinflammation across both organoid models. Key findings included a dose-dependent reduction of critical pro-inflammatory markers such as IL-6 and IL-8 (搜索) in both neuroinflammation models. These effects aligned with prior findings from in vivo Alzheimer's models and ex vivo LPS-induced neuroinflammation models, providing supportive evidence of mechanistic translation from animal models to human tissue systems.
Dr. Eric Hsu, InMed's SVP of Preclinical Research and Development, emphasized the significance of these results: "These results represent an important milestone for INM-901. We have now demonstrated consistent anti-neuroinflammatory effects across multiple in vivo and ex vivo studies, and, importantly, these findings have now been translated into advanced human brain organoid systems. This systematic validation significantly de-risks the program and strengthens our confidence as we advance INM-901 toward human clinical trials."
Comprehensive Preclinical Evidence
The company has built a robust dataset supporting INM-901's anti-neuroinflammatory properties across multiple model systems. In long-term mouse models mimicking Alzheimer's disease, INM-901 significantly reduced inflammatory biomarkers including IFN-γ, TNF-α, IL-1β, KC-GRO, and IL-2, as well as the neurodegenerative marker neurofilament light chain (NfL).
Additionally, in LPS-induced neuroinflammation ex vivo models, the compound significantly reduced inflammasome activation and multiple pro-inflammatory cytokines, including NLRP3 (搜索), IL-1β, IL-6, IL-2, and KC-GRO, demonstrating anti-inflammatory effects independent of amyloid-beta or tau pathology.
Clinical Development Timeline
InMed has outlined a clear pathway toward clinical development for INM-901. The company plans to conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3 2026, while continuing to execute IND-enabling pharmacology and toxicology studies. The company is also advancing drug substance and product manufacturing activities to support IND-enabling studies and submission.
Subject to regulatory feedback and completion of IND-enabling activities, InMed targets submission of an Investigational New Drug (IND) application and initiation of a Phase 1 clinical trial in 2027. The company plans to engage regulatory and clinical experts in neurodegenerative diseases to develop the clinical design for first-in-human trials.
Targeting Neuroinflammation in Alzheimer's Disease
The research addresses a growing recognition of neuroinflammation as a strategic therapeutic target for next-generation Alzheimer's treatments. While recent drug development efforts have largely focused on amyloid plaque and tau pathology, leading to the first disease-modifying therapies in recent years, increasing attention is being directed toward neuroinflammation as a key underlying driver of disease progression.
Studies presented at recent global Alzheimer's conferences have highlighted the relationship between inflammatory biomarkers and the risk of Alzheimer's disease and other dementias, underscoring the growing importance of targeting inflammation. Current research has demonstrated that inflammation emerges as a critical factor influencing long-term patient outcomes.
InMed Pharmaceuticals focuses on developing a pipeline of proprietary small-molecule drug candidates targeting CB1 and CB2 receptors, with programs spanning Alzheimer's, ocular, and dermatological indications. The collaboration with Stem Pharm (搜索) leverages the latter company's proprietary drug discovery platform based on human 3D neuro-immune organoids that model neuroinflammation across various neurological diseases.